Related Experiment Videos
Morganella morganii: a newly reported, rare cause of neonatal sepsis
1Department of Emergency Medicine, Medical Center of Delaware, Christiana Hospital, Newark 19718, USA. Salenp@magpage.com
Abstract:
This case report reviews the clinical course of an 11-day-old boy who developed late-onset neonatal sepsis secondary to a rare neonatal pathogen, Morganella morganii. This gram-negative enteric bacterium, within the Enterobacteriaceae family, has most commonly been a nosocomial pathogen in debilitated, postsurgical patients. Like many other Enterobacteriaceae, M. morganii has an inducible beta-lactamase and is resistant to multiple antibiotics. When caring for neonates with culture-proven M. morganii sepsis, the authors recommend administering both a third-generation cephalosporin and an aminoglycoside to ensure that both antibiotics are bactericidal and to reduce the induction of resistance.
Insights
Late-onset neonatal sepsis caused by Morganella morganii is rare but serious. Treatment with a third-generation cephalosporin and aminoglycoside is recommended for this resistant pathogen.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Microbiology
Background:
- Neonatal sepsis presents a significant health challenge, with gram-negative bacteria being common culprits.
- Morganella morganii, a gram-negative enteric bacterium, is an uncommon cause of neonatal sepsis, typically seen in nosocomial infections.
Observation:
- This case report details an 11-day-old infant experiencing late-onset neonatal sepsis due to Morganella morganii.
- The pathogen, Morganella morganii, exhibits inducible beta-lactamase activity, conferring resistance to multiple antibiotics.
Findings:
- Culture-proven Morganella morganii sepsis in neonates requires careful antibiotic selection.
- The study highlights the challenges in treating this rare neonatal pathogen due to its antibiotic resistance profile.
Implications:
- Combined therapy with a third-generation cephalosporin and an aminoglycoside is suggested for Morganella morganii sepsis.
- This dual-antibiotic approach aims to ensure bactericidal activity and mitigate the development of antibiotic resistance in neonates.